XEN1101 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for XEN1101 comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Depression, and Epilepsy. Most recent publication: A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety., Res Sq, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
    French JA, Porter RJ, Perucca E, et al. · JAMA Neurol · 2023
    PubMed: PMID 37812429 · NCT03796962 (X-TOLE) · Epilepsy
  2. A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety.
    Murrough J, Fremont R, Neukam P, et al. · Res Sq · 2025
    PubMed: PMID 41001561 · NCT04827901 · Depression
  3. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.
    Butterfield NN, Luzon Rosenblut C, Fava M, et al. · JAMA Netw Open · 2025
    PubMed: PMID 40423966 · NCT05376150 (X-NOVA) · Depression

Publications by year

2023–2025: 3 publications.

2023
1
2025
2

Publications by indication

Depression (2)

  • A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety.
    Res Sq · 2025 · PMID 41001561 · NCT04827901
  • Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA Netw Open · 2025 · PMID 40423966 · NCT05376150

Epilepsy (1)

  • Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
    JAMA Neurol · 2023 · PMID 37812429 · NCT03796962

Publications by journal

All XEN1101 publications (3)

2025 (2 papers)

  1. A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety.
    Murrough J, Fremont R, Neukam P, et al. · Res Sq · 2025 · Derived
    PubMed: PMID 41001561 · NCT04827901 · Depression
  2. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.
    Butterfield NN, Luzon Rosenblut C, Fava M, et al. · JAMA Netw Open · 2025 · Derived
    PubMed: PMID 40423966 · NCT05376150 (X-NOVA) · Depression

2023 (1 paper)

  1. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
    French JA, Porter RJ, Perucca E, et al. · JAMA Neurol · 2023 · Trial result
    PubMed: PMID 37812429 · NCT03796962 (X-TOLE) · Epilepsy

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).